Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Developments for a growing Japanese patient population: Facilitating new technologies for future health care

  • Harubumi Kato
  • Toshihide Nishimura
  • Norihiko Ikeda
  • Tesshi Yamada
  • Tadashi Kondo
  • Nagahiro Saijo
  • Kazuto Nishio
  • Junichiro Fujimoto
  • Masaharu Nomura
  • Yoshiya Oda
  • Bertil Lindmark
  • Jiro Maniwa
  • Hitoshi Hibino
  • Michiaki Unno
  • Toshinori Ito
  • Yoshiki Sawa
  • Hiromasa Tojo
  • Shin Egawa
  • Goutham Edula
  • Mary Lopez
  • Murray Wigmore
  • Naohiko Inase
  • Yasuyuki Yoshizawa
  • Fumio Nomura
  • György Marko-Varga
Publiceringsår: 2011
Språk: Engelska
Sidor: 759-764
Publikation/Tidskrift/Serie: Journal of Proteomics2008-01-01+01:00
Volym: 74
Nummer: 6
Dokumenttyp: Artikel i tidskrift
Förlag: Elsevier


Lung cancer, COPD and cardiovascular diseases are highlighted as some of the most common disease that cause mortality, and for that reason are the most active areas for drug development. This perspective paper overviews the urgent need to develop a health care system for a rapidly growing patient population in Japan, including forthcoming demands on clinical care, expecting outcomes, and economics. There is an increasing requirement to build on the strengths of the current health care system, thereby delivering urgent solutions for the future. There is also a declaration from the Ministry of Health, Labour and Welfare (MHLW), to develop new biomarker diagnostics, which is intended for patient stratification, aiding in diagnostic phenotype selection for responders to drug treatment of Japanese patients. This perspective was written by the panel in order to introduce novel technologies and diagnostic capabilities with successful implementation. The next generation of personalized drugs for targeted and stratified patient treatment will soon be available in major disease areas such as, lifestyle-related cancers, especially lung cancers with the highest mortality including a predisposing disorder chronic obstructive pulmonary disease, cardiovascular disease, and other diseases. Mass spectrometric technologies can provide the "phenotypic fingerprint" required for the concept of Personalized Medicine. Mass spectrometry-driven target biomarker diagnoses in combination with high resolution computed tomography can provide a critical pathway initiative facilitated by a fully integrated e-Health infrastructure system. We strongly recommend integrating validated biomarkers based on clinical proteomics, medical imaging with clinical care supported by e-Health model to support personalized treatment paradigms to reduce mortality and healthcare costs of chronic and co-morbid diseases in the elderly population of Japan. (C) 2011 Published by Elsevier B.V.


  • Industrial Biotechnology
  • Lung cancer
  • Chronic Obstructive Pulmonary
  • Disease
  • Proteomics
  • Biomarker
  • Mass spectrometry
  • Diagnosis


  • ISSN: 1874-3919

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen